Next 10 |
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipelin...
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in ha...
2024-03-28 11:53:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Can Fite Biofarma (NYSEMKT: CANF ) just reported results for the fourth quarter of 2023. Can Fite Biofarma reported earnings per share of -1 cent. This was above the analy...
2024-03-28 07:20:31 ET More on Can-Fite Biopharma Seeking Alpha’s Quant Rating on Can-Fite Biopharma Historical earnings data for Can-Fite Biopharma Financial information for Can-Fite Biopharma Read the full article on Seeking Alpha For further...
Ewopharma acquired marketing rights for namodenoson in the treatment of pancreatic carcinoma Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseas...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic a...
Patent has already been issued in other major markets including the U.S., EU, Japan and China Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseas...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the p...
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary smal...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipelin...
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in ha...